Primary research that presents a patient specific case scenario unfolding throughout the report, to 174 high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their open responses on specific clinical decisions.
Patient progression reveals:
Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Triple Negative Metastatic Breast Cancer.
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
Specific patient case scenario that unfolds throughout the report, presented to high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their clinical decisions. Out of 174 oncologists’ responses, those who use combination chemotherapy were most likely to use xx and xx. Oncologists who use a single agent were most likely to use x or x. Key factors in the choice of therapy include the following….